Anthrax immune globulin intravenous (human) - Biologic Drug Details

Summary for anthrax immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	6,979,444	2023-07-22	DrugPatentWatch analysis and company disclosures
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	7,208,160	2023-08-26	DrugPatentWatch analysis and company disclosures
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	7,279,170	2026-06-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for anthrax immune globulin intravenous (human)

Country	Patent Number	Estimated Expiration
Australia	766149
Croatia	P20140081
United Kingdom	0617303

Market dynamics and financial trajectory: Anthrax Immune Globulin Intravenous (Human)

Last updated: May 1, 2026

What is the product and where does it sit in the anthrax biologic landscape?

Anthrax Immune Globulin Intravenous (Human) is a passive-immunization biologic authorized for the treatment of inhalational anthrax in adults and pediatric patients with confirmed anthrax, or in those who have been exposed and are considered at high risk. In the US market, the product is positioned as an adjunct to antimicrobial therapy, not as a standalone antibacterial.

Core market role

• Use model: adjunctive therapy to antibiotics for inhalational anthrax.
• Demand profile: event-driven and channel-dependent (government preparedness buys, hospital pharmacy supply, and stockpiling rather than routine commercial prescribing).
• Competitive setting: other anti-toxin and immune-based approaches are limited; the biologic category relies on preparedness demand more than on broad outpatient markets.

Supply and regulatory footprint

• Regulatory status (US): product is approved and marketed through a manufacturer with access to emergency-use channels and procurement processes tied to biodefense spending.

How do market dynamics shape demand and pricing power?

Demand for anthrax immune globulin is driven by biodefense policy, not by chronic disease prevalence. That structure compresses upside while increasing volatility around procurement cycles.

Key demand drivers

• US government stockpiling and readiness procurement
  • Hospitals and federal agencies maintain preparedness inventories for anthrax scenarios.
  • Purchases occur through contracts and replenishment cycles rather than steady retail sales.
• Regulatory and guideline dependence
  • Uptake rises when treatment pathways for inhalational anthrax explicitly prioritize immunotherapy as an adjunct.
  • Protocol adherence in emergency settings dictates administration frequency.
• Geopolitical and biodefense budgets
  • Funding levels influence inventory build and the timing of replenishment orders.
• Emergency scenario incidence
  • Actual clinical administration is rare; thus, revenue depends on the probability of procurement rather than on event frequency.

Pricing and reimbursement mechanics

• Pricing power is constrained by preparedness procurement
  • Contracts typically cap unit price and may incorporate volume tiers.
• Reimbursement is not analogous to chronic biologics
  • There is no large baseline commercial payer demand. Usage is concentrated in emergency response pathways and pre-arranged supply.

Distribution and inventory dynamics

• Lead times and shelf-life management
  • Biologics require careful inventory planning and cold-chain distribution.
• Order patterns
  • Demand skews toward bulk procurement and replenishment rather than point-of-care replenishment from retail channels.

What is the financial trajectory implied by this market structure?

A passive-immunization anthrax product typically shows a financial pattern of procurement-driven peaks with low underlying baseline sales. For investors and R&D strategists, the critical variable is not treatment incidence but the stability of government and institutional buying.

Expected revenue shape

• Low recurring commercial baseline
  • Routine prescriptions are limited because the indication is narrow and event-driven.
• Revenue spikes around procurement
  • Sales rise when agencies replenish stock or when contracts renew.
• Margin profile tied to biologic manufacturing and contracting
  • Gross margins are influenced by batch economics and contract pricing.

Working capital sensitivity

• Inventory builds and fulfillment timing
  • Revenue can lag procurement orders depending on production schedules.
• Contract terms
  • Payment schedules and delivery milestones affect cash conversion cycles.

Risk profile

• Policy and budgeting risk
  • Funding adjustments can reduce replenishment volumes.
• Manufacturing and supply continuity
  • Any capacity disruption impacts the ability to fulfill contracts, which can delay revenue recognition.

What does the competitive landscape mean for revenue sustainability?

The biologic market for anthrax treatment is structurally small and policy-driven. That means sustainability comes from maintaining “preferred” status in procurement and clinical pathways, not from incremental market share gains typical of broad therapeutic categories.

Competitive levers

• Formulation and route
  • Intravenous immunoglobulin has practical use during acute emergency administration.
• Integration into treatment protocols
  • Products that fit smoothly into standard anthrax algorithms win more procurement preference.
• Manufacturing readiness
  • Agencies favor suppliers that can reliably deliver under surge conditions.

Implication for future financial trajectory

• Defensive moat is operational, not commercial
  • Revenue persistence depends on supply reliability and protocol alignment more than on brand-led demand creation.

How do recent biodefense procurement cycles translate into market outcomes?

For this product class, the observable economic behavior is less about quarterly market discovery and more about procurement scheduling. When governments increase biodefense readiness budgets or renew stockpiles, the product benefits quickly; when budgets compress, replenishment slows and sales flatten.

Business takeaways from procurement-driven markets

• Sales volatility is structurally higher
  • With small baseline demand, contract timing dominates reported results.
• Channel concentration matters
  • Dependence on government and major hospital systems raises concentration risk.
• Long-term growth is incremental
  • Expansion comes from additional contract rounds, not from new indications with large populations.

What are the most decision-relevant metrics for investors and R&D planners?

To track the financial trajectory and market dynamics for Anthrax Immune Globulin Intravenous (Human), the decision metrics should focus on procurement and supply-chain throughput.

Metrics that drive valuation and program planning

• Number and size of biodefense contracts
• Delivery schedules versus order timing
• Inventory replenishment frequency
• Manufacturing capacity utilization
• Unit economics under contract pricing
• Formulary or guideline inclusion status (where documented)
• Supply continuity and any manufacturing disruption history

Key Takeaways

• Anthrax Immune Globulin Intravenous (Human) sells into a biodefense and emergency-preparedness model, so revenue is procurement-driven with a limited commercial baseline.
• Market dynamics are dominated by government readiness purchases, protocol adherence, and budgeting cycles rather than by routine clinical demand.
• The financial trajectory typically shows spiky revenue around replenishment and contract renewals, with margins and cash flow influenced by biologic manufacturing economics and delivery milestones.
• Competitive durability rests on operational reliability and protocol fit more than on broad market share expansion.

FAQs

1) Is anthrax immune globulin a mass-market biologic?

No. The indication is narrow and event-driven, so demand largely tracks preparedness procurement and emergency response pathways rather than routine prescribing.

2) What drives quarterly revenue changes most for this product type?

The timing of biodefense stockpile contracts, replenishment deliveries, and fulfillment milestones.

3) How does competition affect pricing power in this category?

Competition is limited in practice; pricing is more constrained by contract structures and procurement frameworks than by typical commercial payer competition.

4) What operational factors most affect financial performance?

Manufacturing capacity, batch economics, cold-chain distribution readiness, and delivery schedule adherence under contract terms.

5) What is the main pathway to revenue growth?

Additional government or institutional procurement volumes and renewed contract awards, not expansion into broad patient populations.

---

References (APA)

[1] FDA. (n.d.). Anthrax Immune Globulin Intravenous (Human). U.S. Food and Drug Administration. https://www.fda.gov/
[2] US Department of Health and Human Services. (n.d.). Biodefense and preparedness resources related to anthrax. https://www.hhs.gov/
[3] National Institutes of Health. (n.d.). Clinical management guidance and background on anthrax treatment approaches. https://www.nih.gov/
[4] Centers for Disease Control and Prevention. (n.d.). Anthrax clinical information and treatment overview. https://www.cdc.gov/